Cabaletta Bio to Discuss Curative Cell Therapies at Investor Conference

Cabaletta Bio will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, to discuss its CABA platform and pipeline. The company's management team will provide an update on its progress and clinical trials for autoimmune diseases.

author-image
Bijay Laxmi
New Update
Cabaletta Bio to Discuss Curative Cell Therapies at Investor Conference

Cabaletta Bio to Discuss Curative Cell Therapies at Investor Conference

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing curative targeted cell therapies for patients with autoimmune diseases, will participate, annual, investor, conference on Monday, May 20, 2024. The event will take place at the NASDAQ in New York City.

Why this matters: The development of curative cell therapies for autoimmune diseases has the potential to revolutionize the treatment landscape and improve the lives of millions of people worldwide. As autoimmune diseases are a significant burden on healthcare systems, advancements in this field could have far-reaching implications for public health and healthcare policy.

Cabaletta's management team is scheduled for a fireside chat at 9:30 a.m. ET to discuss the company's CABA platform, which encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody receptor T cells). The company's lead product candidate, CABA-201, a 4-1BB-containing fully human CD19-CAR T, is currently being evaluated in the participate clinical trials for systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.

"Our CABA platform has the potential to deliver curative targeted cell therapies for patients suffering from a range of autoimmune diseases," said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta Bio. look forward "We look forward to providing an update on our progress and pipeline at the upcoming H.C. Wainwright conference."

In addition to CABA-201, Cabaletta's pipeline includes multiple clinical-stage CAART candidates. DSG3-CAART is in development for the treatment of mucosal pemphigus vulgaris, while MuSK-CAART is being investigated as a potential therapy for MuSK myasthenia gravis. The company's research and development facilities are located in Philadelphia, Pennsylvania.

A live webcast of Cabaletta's presentation at the H.C. Wainwright conference will be available on the News and Events section of the company's website at www.cabalettabio.com. A replay of the webcast will be accessible on the website for 30 days following the event. Investors and other interested parties can contact Anup Marda, Cabaletta's Chief Financial Officer, at investors@cabalettabio.com, or William Gramig of Stern Investor Relations, Inc. at william.gramig@sternir.com for more information.

Cabaletta Bio's participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference underscores the company's commitment to advancing its pipeline of curative targeted cell therapies for autoimmune diseases. With its novel CABA platform and multiple clinical-stage candidates, Cabaletta aims to transform the treatment landscape and improve outcomes for patients with limited therapeutic options.

Key Takeaways

  • Cabaletta Bio to participate in H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024.
  • The company's CABA platform aims to deliver curative targeted cell therapies for autoimmune diseases.
  • CABA-201, a CD19-CAR T, is being evaluated in clinical trials for systemic lupus erythematosus and other diseases.
  • Cabaletta's pipeline includes multiple clinical-stage CAART candidates for various autoimmune diseases.
  • A live webcast of the presentation will be available on Cabaletta's website, with a replay accessible for 30 days.